Form 4: Xilio Therapeutics Director Christina Rossi Reports Stock Option Grant

Christina Rossi, a director of Xilio Therapeutics, reported the grant of a stock option for 25,000 shares on June 14, 2024.

Summary

• Christina Rossi, a director at Xilio Therapeutics, Inc. (XLO), filed a Form 4 on June 17, 2024, reporting a transaction.
• The transaction involved the grant of a stock option to Rossi on June 14, 2024, for 25,000 shares of XLO common stock at an exercise price of $1.02 per share.
• The options vest on the earlier of June 14, 2025, or the date of the next annual meeting of stockholders, contingent upon Rossi's continued service to the company.
• Rossi also has a power of attorney designating Ren Russo, Christopher Frankenfield, Kevin Brennan, and Julia Walcott to handle Section 16 reporting obligations.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of stock options to directors can align their interests with those of shareholders, incentivizing them to work towards the company's success.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to continued service, suggesting an expectation of ongoing contributions from the director.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year or the next annual meeting is fairly typical.
• Comparable companies like BioNTech or Moderna also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director to contribute to the company's success, which could benefit all stakeholders.

Key Dates